Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
31 hedge funds and large institutions have $10.2M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
11% more funds holding
Funds holding: 28 → 31 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less capital invested
Capital invested by funds: $13.2M → $10.2M (-$2.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
+$591K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$559K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$242K |
| 4 |
Renaissance Technologies
New York
|
+$242K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$117K |
| 2 |
BlackRock
New York
|
-$71.6K |
| 3 |
TFA
Tobias Financial Advisors
Plantation,
Florida
|
-$39K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$23.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14K |
OPNT Hedge Fund Activity: Q1 2020 in Review
31 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2020, worth a combined $10.2M — down 22% from $13.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OPNT positions and 3 closed out — a net gain of 5 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Fondren Management, adding an estimated $591K. The largest seller was Wedge Capital Management, cutting an estimated $117K.
- 31 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2020, up from 28 in Q4 2019.
- Funds reported $10.2M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 22% quarter-over-quarter.
- 8 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 3 closed out, a net change of +5 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Fondren Management, an estimated $591K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Wedge Capital Management, an estimated $117K sold.
Based on aggregated 13F filings for Q1 2020.